Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Amyloid beta precursor protein binding family B member 1 (APBB1, also known as FE65) is a nuclear-localized adaptor protein of the Fe65 protein family. It interacts directly with the cytoplasmic tail of amyloid precursor protein (APP) and is involved in the transcriptional regulation of genes, modulation of apoptosis, and cell cycle progression. APBB1 is proposed to play an important role in Alzheimer’s disease pathogenesis due to its association with APP and effects on amyloid processing and nuclear signaling. It is also implicated in learning, memory, and the maintenance of neuronal and muscle functions[1][2][3][11]. Multiple alternatively spliced isoforms exist, with some differences in their nuclear signaling potential. APBB1 interacts with various partners including APP, APLP2, transcription factor CP2/LSF/LBP1, and LRP1, supporting its role as a key signal integration molecule in the central nervous system[1][3][8][11].
null (adapter protein; drugs modulating APP processing may be indirectly relevant, but no direct targeting mechanism described)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Amyloid beta precursor protein binding family B member 1 (APBB1).